Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène (INMG)-MeLis, INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, 69373, Lyon, France. jerome.honnorat@chu-lyon.fr.
French Reference Centre On Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677, Bron Cedex, France. jerome.honnorat@chu-lyon.fr.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène (INMG)-MeLis, INSERM U1314, CNRS UMR 5284, Université de Lyon, Université Claude Bernard Lyon 1, 69373, Lyon, France.
French Reference Centre On Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677, Bron Cedex, France.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
Clinical Neurology Unit, Santa Maria della Misericordia University Hospital, Piazzale Santa Maria della Misericordia, 15, 33010, Udine, Italy. alberto.vogrig@gmail.com.
French Reference Center on Paraneoplastic Neurological Syndrome and Autoimmune Encephalitis, Hospital for Neurology and Neurosurgery Pierre Wertheimer, Lyon University Hospital, Lyon, France. alberto.vogrig@gmail.com.
SynatAc Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon, France. alberto.vogrig@gmail.com.
University Claude Bernard Lyon 1, University of Lyon, Lyon, France. alberto.vogrig@gmail.com.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
From the Department of Neurology (I.H., M.H., C.T., C.V.), Haukeland University Hospital; Department of Clinical Medicine (I.H., K.M., C.V.), University of Bergen; and Departments of Neurology and Clinical Medicine (I.H., C.T., C.V.), Neuro-SysMed-Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
From the Division of Neuropathology and Neurochemistry (M.W., V.E., C.S., G.R., R.H.), Department of Neurology, and Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; Department of Electrical and Electronics Engineering (M.M.), Faculty of Engineering, Nagasaki Institute of Applied Science; Department of Neurology and Strokology (S.Y.), Nagasaki University Hospital; Neurology Clinic with Neuromorphomics Laboratory (H.S.), Nitobe Memorial Nakano General Hospital, Tokyo; Division of Surgical Pathology (H.S.), Tokyo Medical and Dental University Hospital; The Center for Personalized Medicine for Healthy Aging (K.I.), Tokyo Medical and Dental University; Departments of Diagnostic Pathology and Clinical Laboratory (Y.T.), Yokosuka Kyosai Hospital, Kanagawa; Department of Neurology (T. Iizuka), Kitasato University School of Medicine, Kanagawa; Department of Neurology and Neurological Science (T.Y.), Graduate School, Tokyo Medical and Dental University; and Department of Neurology (T. Irioka), Yokosuka Kyosai Hospital, Kanagawa, Japan.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
From the Division of Neuropathology and Neurochemistry (M.W., V.E., C.S., G.R., R.H.), Department of Neurology, and Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; Department of Electrical and Electronics Engineering (M.M.), Faculty of Engineering, Nagasaki Institute of Applied Science; Department of Neurology and Strokology (S.Y.), Nagasaki University Hospital; Neurology Clinic with Neuromorphomics Laboratory (H.S.), Nitobe Memorial Nakano General Hospital, Tokyo; Division of Surgical Pathology (H.S.), Tokyo Medical and Dental University Hospital; The Center for Personalized Medicine for Healthy Aging (K.I.), Tokyo Medical and Dental University; Departments of Diagnostic Pathology and Clinical Laboratory (Y.T.), Yokosuka Kyosai Hospital, Kanagawa; Department of Neurology (T. Iizuka), Kitasato University School of Medicine, Kanagawa; Department of Neurology and Neurological Science (T.Y.), Graduate School, Tokyo Medical and Dental University; and Department of Neurology (T. Irioka), Yokosuka Kyosai Hospital, Kanagawa, Japan.
Publications dans "Dégénérescence cérébelleuse paranéoplasique" :
Purkinje cell cytoplasmic autoantibody type 1 (PCA1), also known as anti-Yo, is a 'high-risk' paraneoplastic antibody, associated with rapidly progressive cerebellar syndrome. In patients with this sy...
Patients with ovarian cancer (OC) may develop anti-Yo-associated paraneoplastic cerebellar degeneration (PCD)-a cerebellar ataxia associated with tumor-induced autoimmunity against CDR2 and CDR2L prot...
Serum exosomes were isolated from patients with OC (n = 15), patients with OC and anti-Yo-associated PCD (n = 14) and healthy controls (HC, n = 15). Small RNA sequencing was used to identify different...
OC patients with PCD exhibited a distinct exosomal miRNA expression profile. We detected 103 differentially expressed exosomal miRNAs in PCD patients compared to OC patients without PCD and 139 differ...
Our results demonstrate that OC patients with anti-Yo-associated PCD exhibit a distinct exosomal miRNA profile compared to OC patients without PCD. Several of the differentially expressed exosomal miR...
A 77-year-old female with a subacute progression of ataxia and serum anti-Yo antibodies was suspected to have paraneoplastic cerebellar degeneration (PCD). An examination of an underlying cancer showe...
Paraneoplastic neurological syndromes (PNSs) are an uncommon complication of cancer, affecting nearby 1/10,000 subjects with a tumour. PNSs can involve all the central and peripheral nervous systems, ...
A 61-year-old woman with a history of untreated low-grade B-cell lymphoma presented with blurry vision, unsteadiness, and worsening pain on touching skin of the upper trunk was enrolled. Blurry vision...
Co-occurring anti-tripartite motif-containing protein 9 and 67 autoantibodies (TRIM9/67-IgG) have been reported in only a very few cases of paraneoplastic cerebellar syndrome. The value of these bioma...
We performed a retrospective, multicenter study to evaluate the cerebrospinal fluid and serum of candidate TRIM9/67-IgG cases by tissue-based immunofluorescence, peptide phage display immunoprecipitat...
Among these cases (n = 13), CBA was the most sensitive (100%) and revealed that all cases had TRIM9 and TRIM67 autoantibodies. Of TRIM9/67-IgG cases with available clinical history, a subacute cerebel...
TRIM9/67-IgG is a rare but likely high-risk paraneoplastic biomarker for which CBA appears to be the most sensitive diagnostic assay. ANN NEUROL 2023;94:1086-1101....
Paraneoplastic neurological syndromes (PNS) are a group of disorders with diverse neurological manifestations that are observed in patients with various types of cancer. Any portion of the nervous sys...
Paraneoplastic neurologic degeneration (PND) manifests as a sudden or subacute neurological syndrome often linked to underlying cancer, either overt or subclinical. Within the spectrum of PND, subacut...
Malignancy-associated cerebellar hypermetabolism on [ 18 F]FDG PET/CT has 2 major causes: paraneoplastic autoimmune encephalitis and neoplasias (leptomeningeal/cerebellar metastases and primary cerebe...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, and the association with immune-related adverse events (irAEs) is well-established. However, cerebellar irAEs are poorly defined...